EU, Gilead in talks over remdesivir doses - report

Wednesday, 01. July 2020 18:26

The European Commission and Gilead Sciences are in negotiations to secure doses of remdesivir for the bloc so member states could use the drug in COVID-19 treatments, Channel 4 News reported on Wednesday.

The EU wants to reserve doses for the drug after the United States confirmed it had bought almost 100% of global remdesivir supply from Gilead.

The European Medicines Agency previously recommended remdesivir to treat COVID-19. Gilead priced the drug at $2,340 per treatment.

Related Links: Gilead Sciences Inc.
Breaking the News / VP